237 related articles for article (PubMed ID: 35049693)
1. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
Aduquaye M; Dube S; Bashir B; Chowdhury A; Ahmed N; Leylek A; Kim J; Lambert P; Bucher O; Hunter W; Sivananthan G; Koul R; Rathod S
Curr Oncol; 2022 Jan; 29(1):193-208. PubMed ID: 35049693
[TBL] [Abstract][Full Text] [Related]
2. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
8. Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy.
Huang K; Prasad S; Ma SJ; Yu H; Iovoli AJ; Farrugia MK; Dexter EU; Demmy TL; Malik NK; Singh AK
BMC Cancer; 2023 Mar; 23(1):254. PubMed ID: 36932396
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
Park Y; Chang AR
Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
[TBL] [Abstract][Full Text] [Related]
12. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer.
Shoji F; Kozuma Y; Toyokawa G; Yamazaki K; Takeo S
Ann Thorac Cardiovasc Surg; 2020 Oct; 26(5):248-255. PubMed ID: 32074540
[TBL] [Abstract][Full Text] [Related]
13. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
[TBL] [Abstract][Full Text] [Related]
14. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
15. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
17. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
[TBL] [Abstract][Full Text] [Related]
18. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
20. Combination of preoperative neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio: a superior prognostic factor of endometrial cancer.
Cong R; Kong F; Ma J; Li Q; Wu Q; Ma X
BMC Cancer; 2020 May; 20(1):464. PubMed ID: 32448185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
